Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Surprise! Saturn's huge moon Titan may not have a buried ocean after all - 2Instructions to Pick the Right Dental Expert for Teeth Substitution
- 3Enormous Credit And All that You Really want To Be aware
- 4How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
- 5What is colostrum? And should you be taking it?
- South Korea president says Iran war shows the need to ditch ‘extremely risky’ fossil fuels
- IVE 2026 'Show What I Am' Tour: How to get tickets, prices, dates and more
- Email Promoting Instruments for Compelling Efforts
- Building a Maintainable Closet: Individual Excursions in Moral Style
- Iran war pushes Germany's deficit to 4.2% as growth outlook is cut by 50%
- Climbing Mount Everest: An Individual Victory
- A quick recap of 'Stranger Things' Seasons 1-4, plus key episodes to rewatch before Volume 1 of the final season drops
- Southern Californians, your health insurance costs could rise in 2026
- Astronauts head home early after medical issue
